drugset / Trial / NCT06332638
PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to explore pharmacokinetics, pharmacodynamics, and safety of tegoprazan 12.5 mg in healthy subjects when orally administered as a single dose or as multiple doses twice daily.
Timeline
- Start
- 2024-03-19
- Primary completion
- 2024-07-31
- Completion
- 2024-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Famotidine | Other / unclassified | 20 mg | Oral |
| Subject | Tegoprazan | Other / unclassified | 12.5 mg | Oral |
| Subject | Tegoprazan | Other / unclassified | 25 mg | Oral |
Indications
No indication recorded.